Mydecine Innovations Group Inc.

CNSX:MYCO Stock Report

Market Cap: CA$506.1k

Mydecine Innovations Group Management

Management criteria checks 3/4

Mydecine Innovations Group's CEO is Josh Bartch, appointed in Jul 2018, has a tenure of 6.5 years. directly owns 0.61% of the company’s shares, worth CA$3.08K. The average tenure of the management team and the board of directors is 4.2 years and 4.6 years respectively.

Key information

Josh Bartch

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.5yrs
CEO ownership0.6%
Management average tenure4.2yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Bartch's remuneration changed compared to Mydecine Innovations Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$12m

Jun 30 2024n/an/a

-CA$12m

Mar 31 2024n/an/a

-CA$11m

Dec 31 2023n/an/a

-CA$21m

Sep 30 2023n/an/a

-CA$19m

Jun 30 2023n/an/a

-CA$20m

Mar 31 2023n/an/a

-CA$21m

Dec 31 2022CA$445kCA$383k

-CA$16m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$18m

Mar 31 2022n/an/a

-CA$24m

Dec 31 2021CA$2mCA$346k

-CA$24m

Sep 30 2021n/an/a

-CA$19m

Jun 30 2021n/an/a

-CA$37m

Mar 31 2021n/an/a

-CA$32m

Dec 31 2020CA$819kCA$153k

-CA$27m

Sep 30 2020n/an/a

-CA$39m

Jun 30 2020n/an/a

-CA$23m

Mar 31 2020n/an/a

-CA$20m

Dec 31 2019CA$238kCA$238k

-CA$21m

Sep 30 2019n/an/a

-CA$5m

Jun 30 2019n/an/a

-CA$5m

Mar 31 2019n/an/a

-CA$11m

Dec 31 2018CA$425kCA$302k

-CA$13m

Compensation vs Market: Insufficient data to establish whether Josh's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.

CEO

Josh Bartch (36 yo)

6.5yrs

Tenure

CA$444,518

Compensation

Mr. David Joshua Bartch, also known as Josh, serves as Chairman of the Board at Mydecine Innovations Group Inc. Mr. Bartch is Co-Founder of Mydecine Innovations Group Inc. and serves as its President, Chie...

Leadership Team

NamePositionTenureCompensationOwnership
David Bartch
Co-Founder6.5yrsCA$444.52k0.61%
CA$ 3.1k
Robert Roscow
Co-Founder4.7yrsCA$455.31kno data
Damon Michaels
Co-Founder & COO4.7yrsCA$455.31k0.15%
CA$ 744.9
John Ross
CFO & Corporate Secretary2.3yrsCA$9.20kno data
Sanford Stein
Chief Compliance Officer & General Counsel4.3yrsCA$317.36kno data
Rakesh Jetly
Chief Medical Officer4.2yrsCA$271.20kno data
Morgan Kervitsky
Director of Marketingno datano datano data
Michel Rudolphie
President of the European Operations3.8yrsno datano data
William Cook
Interim CEO & Technical Director of Mindleap Health Inc.3.7yrsno datano data

4.2yrs

Average Tenure

Experienced Management: MYCO's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Bartch
Co-Founder6.6yrsCA$444.52k0.61%
CA$ 3.1k
Robert Roscow
Co-Founder4.1yrsCA$455.31kno data
Anton Gomez-Escolar
Member of Medical4.6yrsno datano data
Vince Polito
Member of Medical4.6yrsno datano data
Denton Hoyer
Member of Medical4.6yrsno datano data
Ruth Lanius
Member of Medicalno datano datano data
Gary Wynn
Member of Medicalno datano datano data
Paul Frewen
Member of Medicalno datano datano data
Rick Barnett
Member of Medicalno datano datano data
Danielle Wise
Member of Medicalno datano datano data
David Erritzoe
Member of Medical4.4yrsno datano data
Robin Carhart-Harris
Member of Medical4.4yrsno datano data

4.6yrs

Average Tenure

Experienced Board: MYCO's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 01:20
End of Day Share Price 2025/01/15 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mydecine Innovations Group Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward StaceyCapital Network by Proactive Investors
Elemer PirosRoth Capital Partners